Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.

Hernández-Bernal F, Subirós-Martínez N, Gutiérrez-Ronquillo JH, Colina-Ávila E, Guevara-Rodríguez M, Estenoz-García D, Catasús-Álvarez K, Martín-Bauta Y, Pérez-Saad H, Manso-López AM, Batista-Izquierdo A, González-Dalmau E and 4 more

Show all authors

Amador-Nuñez T, Muzio-González VL, Guillén-Nieto GE, Garcia-Del-Barco-Herrera D

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia16 Jul 2026

PMID42462342DOI10.1016/j.jocn.2026.112195PepBankPUB-42462342

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In adults with acute ischemic stroke, EGF plus GHRP6 did not change mRS compared with standard care in the intention-to-treat population.
In plain wordsIn adults with acute stroke, the EGF and GHRP6 combination did not improve disability scores compared with standard care.
Peptide
GHRP-6
Outcome
No significant changeModified Rankin Scale (mRS) in the intention-to-treat population
Study
n = 188
Comparator
Standard care
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In the intention-to-treat population, no differences were found in mRS, Barthel index nor survival.
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234202
02HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In adults with acute ischemic stroke, EGF plus GHRP6 did not change the Barthel index compared with standard care in the intention-to-treat population.
In plain wordsIn adults with acute stroke, the EGF and GHRP6 combination did not change daily-living scores compared with standard care.
Peptide
GHRP-6
Outcome
No significant changeBarthel index in the intention-to-treat population
Study
n = 188
Comparator
Standard care
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In the intention-to-treat population, no differences were found in mRS, Barthel index nor survival.
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234203
03HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In adults with acute ischemic stroke, EGF plus GHRP6 did not change survival compared with standard care in the intention-to-treat population.
In plain wordsIn adults with acute stroke, the EGF and GHRP6 combination did not change survival compared with standard care.
Peptide
GHRP-6
Outcome
No significant changeSurvival in the intention-to-treat population
Study
n = 188
Comparator
Standard care
Analysis
Secondary
Outcome group
Mortality · Nervous system and cognition
Source sentences
Summary
In the intention-to-treat population, no differences were found in mRS, Barthel index nor survival.
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234204
04HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In patients with middle cerebral artery stroke, EGF plus GHRP6 gave a greater infarct volume reduction at 30 days than standard care.
In plain wordsIn stroke of the middle cerebral artery area, EGF with GHRP6 was linked to a larger fall in infarct size at 30 days.
Peptide
GHRP-6
Outcome
DecreaseInfarct volume reduction in the middle cerebral artery territory
Study
n: not reported in source
Comparator
Standard care
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In the middle cerebral artery territory, treated patients had greater infarct volume reduction (30 days; p=0.041).
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234207
05HumanNot a test of GHRP-6 aloneRandomized controlled trialSafety outcome
In adults with acute ischemic stroke, severe adverse events occurred in 30 of 95 patients given EGF plus GHRP6 and 48 of 188 overall; none were treatment-related and the odds ratio was 1.92.
In plain wordsIn adults with acute stroke, severe adverse events were not clearly more frequent with the EGF and GHRP6 combination than with standard care.
Peptide
GHRP-6
Outcome
No significant changeSevere adverse events
Study
n = 188
Comparator
Standard care
Outcome group
Adverse events · Nervous system and cognition
Measurements
Odds ratio
1.92
severe adverse events, treated vs control
Source sentences
Summary
Severe adverse events occurred in 48/188 patients (none treatment-related), with 30/95 in the treated group (OR=1.92; 95%CI: 0.981-3.767).
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234201
06HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In patients with severe stroke (NIHSS 15 or higher), EGF plus GHRP6 reduced disability at 6 months (mRS 2.6 versus 4.7 with control).
In plain wordsIn patients with severe stroke, the EGF and GHRP6 combination was linked to less disability at 6 months than standard care.
Peptide
GHRP-6
Outcome
DecreasemRS at 6 months in severe stroke (NIHSS 15 or higher)
Study
n = 27
Comparator
Standard care
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
mRS at 6 months
2.6
EGF+GHRP6, NIHSS 15 or higher
mRS at 6 months
4.7
control, NIHSS 15 or higher
Source sentences
Summary
However, severe-stroke patients (NIHSS≥15, n=27) treated with EGF+GHRP6 showed reduced disability (mRS_6-months=2.6, 95%CI: 1.3-3.8 vs Control 4.7, 95%CI: 2.6-6; p=0.03
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234205
07HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In patients with severe stroke (NIHSS 15 or higher), EGF plus GHRP6 reduced the risk of death (hazard ratio 0.18).
In plain wordsIn patients with severe stroke, the EGF and GHRP6 combination was linked to a lower risk of death than standard care.
Peptide
GHRP-6
Outcome
DecreaseMortality risk in severe stroke (NIHSS 15 or higher)
Study
n = 27
Comparator
Standard care
Outcome group
Mortality · Nervous system and cognition
Measurements
Hazard ratio for mortality
0.18
EGF+GHRP6 vs control, NIHSS 15 or higher
Source sentences
Summary
and mortality risk (HR=0.18, 95%CI: 0.03-0.96; p=0.045
3 context sentences(design, population, supporting numbers)
Summary · context
However, severe-stroke patients (NIHSS≥15, n=27
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234206
08HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In a sensitivity analysis with an NIHSS threshold of 12 or higher, outcomes with EGF plus GHRP6 were similar to those in the severe-stroke subgroup.
In plain wordsIn patients with moderate-to-severe stroke, the EGF and GHRP6 combination gave results similar to those in the severe-stroke group.
Peptide
GHRP-6
Outcome
Direction not reportedOutcomes with NIHSS 12 or higher threshold (sensitivity analysis)
Study
n: not reported in source
Comparator
Standard care
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Similar outcomes were found using NIHSS≥12 threshold.
2 context sentences(design, population, supporting numbers)
Summary · context
A multicenter, randomized, open-label, phase-III trial enrolled patients within 12 hours of symptom onset, and NIHSS score of 5-20.
Summary · context
Participants received the combined therapy (n=95; twice daily, 7 days) or standard care (n=93).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4246234208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.